|
US6369116B1
(en)
*
|
1995-06-02 |
2002-04-09 |
Oculex Pharmaceuticals, Inc. |
Composition and method for treating glaucoma
|
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
|
DE69716586T2
(de)
*
|
1996-03-05 |
2003-07-17 |
Robert Gurny |
Gepufferte orthoesterpolymere enthaltende arzneimittel
|
|
FR2748205A1
(fr)
*
|
1996-05-06 |
1997-11-07 |
Debio Rech Pharma Sa |
Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
|
|
US5942508A
(en)
*
|
1997-02-04 |
1999-08-24 |
Senju Pharmaceutical Co., Ltd. |
Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
|
|
AU738338B2
(en)
*
|
1997-08-11 |
2001-09-13 |
Allergan, Inc. |
Sterile bioerodible implant device with improved biocompatability and method
|
|
IN186245B
(enExample)
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
|
US7399480B2
(en)
*
|
1997-09-26 |
2008-07-15 |
Abbott Laboratories |
Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
|
|
US20030129215A1
(en)
*
|
1998-09-24 |
2003-07-10 |
T-Ram, Inc. |
Medical devices containing rapamycin analogs
|
|
US6890546B2
(en)
*
|
1998-09-24 |
2005-05-10 |
Abbott Laboratories |
Medical devices containing rapamycin analogs
|
|
US7445792B2
(en)
*
|
2003-03-10 |
2008-11-04 |
Abbott Laboratories |
Medical device having a hydration inhibitor
|
|
DE19756314C2
(de)
*
|
1997-12-12 |
2000-06-29 |
Roland Bodmeier |
Zubereitung mit verlängerter Verweildauer am Applikationsort
|
|
EP0985413A1
(de)
*
|
1998-08-06 |
2000-03-15 |
Jörg Michael Dr. Dr. Schierholz |
Medizinprodukte mit retardierter pharmakologischer Aktivität und Verfahren zu ihrer Herstellung
|
|
DE59913045D1
(de)
*
|
1998-08-06 |
2006-04-06 |
Schierholz Joerg Michael |
Medizinprodukte mit retardierter pharmakologischer aktivität und verfahren zu ihrer herstellung
|
|
US7455853B2
(en)
*
|
1998-09-24 |
2008-11-25 |
Abbott Cardiovascular Systems Inc. |
Medical devices containing rapamycin analogs
|
|
FR2770134B1
(fr)
*
|
1998-10-28 |
2002-06-07 |
Delab |
Formulations solides ou semi-solides pour administration locale
|
|
CA2358296A1
(en)
*
|
1999-01-05 |
2000-07-13 |
Anthony P. Adamis |
Targeted transscleral controlled release drug delivery to the retina and choroid
|
|
US6113638A
(en)
*
|
1999-02-26 |
2000-09-05 |
Williams; Lytton A. |
Method and apparatus for intervertebral implant anchorage
|
|
US6331313B1
(en)
*
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
|
US7708711B2
(en)
*
|
2000-04-14 |
2010-05-04 |
Glaukos Corporation |
Ocular implant with therapeutic agents and methods thereof
|
|
US20010049422A1
(en)
*
|
2000-04-14 |
2001-12-06 |
Phaneuf Matthew D. |
Methods of applying antibiotic compounds to polyurethane biomaterials using textile dyeing technology
|
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
|
US6692759B1
(en)
*
|
2000-06-28 |
2004-02-17 |
The Regents Of The University Of California |
Methods for preparing and using implantable substance delivery devices
|
|
EP1637126B1
(en)
*
|
2000-07-05 |
2016-12-14 |
Allergan, Inc. |
Methods for treating inflammation of the eye
|
|
US6726918B1
(en)
*
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
|
RU2206298C2
(ru)
*
|
2000-09-22 |
2003-06-20 |
Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" |
Способ лечения глаукомы
|
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
|
US20030082183A1
(en)
*
|
2000-11-01 |
2003-05-01 |
Wheeler Larry A. |
Methods and compositions for treatment of ocular neovascularization and neural injury
|
|
AU2002248284A1
(en)
*
|
2000-11-01 |
2002-08-06 |
Allergan, Inc. |
Compositions for treatment of ocular neovascularization
|
|
EP1621219A3
(en)
*
|
2000-11-29 |
2006-03-22 |
Allergan, Inc. |
Intraocular implants for preventing transplant rejection in the eye
|
|
WO2002043785A2
(en)
|
2000-11-29 |
2002-06-06 |
Oculex Pharmaceuticals, Inc. |
Intraocular implants for preventing transplant rejection in the eye
|
|
KR100446101B1
(ko)
*
|
2000-12-07 |
2004-08-30 |
주식회사 삼양사 |
수난용성 약물의 서방성 제형 조성물
|
|
US20020082678A1
(en)
*
|
2000-12-22 |
2002-06-27 |
Motasim Sirhan |
Intravascular delivery of mizoribine
|
|
JP4657577B2
(ja)
*
|
2001-01-09 |
2011-03-23 |
マイクロチップス・インコーポレーテッド |
眼への適用および他への適用のための可撓性マイクロチップデバイス
|
|
US7431710B2
(en)
|
2002-04-08 |
2008-10-07 |
Glaukos Corporation |
Ocular implants with anchors and methods thereof
|
|
WO2002089767A1
(en)
|
2001-05-03 |
2002-11-14 |
Massachusetts Eye And Ear Infirmary |
Implantable drug delivery device and use thereof
|
|
US7592016B2
(en)
*
|
2001-06-28 |
2009-09-22 |
Regents Of The University Of California |
Methods for preparing and using implantable substance delivery devices
|
|
GB0116920D0
(en)
*
|
2001-07-11 |
2001-09-05 |
Sulzer Vascutek Ltd |
Delivery system
|
|
US20080145402A1
(en)
*
|
2001-09-10 |
2008-06-19 |
Abbott Cardiovascular Systems Inc. |
Medical Devices Containing Rapamycin Analogs
|
|
WO2003070219A1
(en)
*
|
2002-02-22 |
2003-08-28 |
Santen Pharmaceutical Co., Ltd. |
Drug delivery system for the subconjunctival administration of fine grains
|
|
US20030180294A1
(en)
*
|
2002-02-22 |
2003-09-25 |
Devries Gerald W. |
Methods of extending corneal graft survival
|
|
EP1482914B1
(en)
*
|
2002-03-11 |
2015-04-22 |
Novartis AG |
Implantable drug delivery device for the eye
|
|
US7074426B2
(en)
*
|
2002-03-27 |
2006-07-11 |
Frank Kochinke |
Methods and drug delivery systems for the treatment of orofacial diseases
|
|
AU2003217531A1
(en)
*
|
2002-05-02 |
2003-11-17 |
Massachusetts Eye And Ear Infirmary |
Ocular drug delivery systems and use thereof
|
|
MXPA04011416A
(es)
|
2002-05-17 |
2005-09-30 |
Othera Pharmaceuticals Inc |
Mejora del desarrollo de las cataratas y otras enfermedades oftalmicas.
|
|
EP1509256B1
(en)
*
|
2002-05-24 |
2009-07-22 |
Angiotech International Ag |
Compositions and methods for coating medical implants
|
|
RU2207093C1
(ru)
*
|
2002-05-28 |
2003-06-27 |
Государственное учреждение Тверская государственная медицинская академия |
Способ временного склерального пломбирования с применением эксплантатов из полигликолидного волокна
|
|
CN100589809C
(zh)
*
|
2002-06-13 |
2010-02-17 |
诺瓦提斯公司 |
季铵环糊精化合物
|
|
US20070184089A1
(en)
*
|
2002-07-15 |
2007-08-09 |
Alcon, Inc. |
Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
|
|
JP4463681B2
(ja)
|
2002-07-15 |
2010-05-19 |
アルコン，インコーポレイテッド |
眼内使用のための非ポリマー親油性薬学的インプラント組成物
|
|
DE10238310A1
(de)
*
|
2002-08-21 |
2004-03-04 |
Erich Jaeger Gmbh |
Elektrodenanordnung
|
|
CZ294328B6
(cs)
*
|
2002-08-22 |
2004-11-10 |
Pliva-Lachema A. S. |
Biodegradabilní kompozice s prolongovaným uvolňováním biologicky aktivní látky a způsob její výroby
|
|
BR0314013A
(pt)
*
|
2002-09-06 |
2005-07-12 |
Abbott Lab |
Equipamento médico contendo inibidor de hidratação
|
|
WO2004028477A2
(en)
*
|
2002-09-29 |
2004-04-08 |
Surmodics, Inc. |
Methods for treatment and/or prevention of retinal disease
|
|
AU2003301347A1
(en)
*
|
2002-10-17 |
2004-05-04 |
Control Delivery Systems, Inc. |
Methods for monitoring treatment of disease
|
|
JP2006505562A
(ja)
*
|
2002-10-17 |
2006-02-16 |
アルカーメス コントロールド セラピューティクス，インコーポレイテッド |
持続放出組成物の放出プロフィールの調節方法
|
|
KR20050085367A
(ko)
*
|
2002-12-04 |
2005-08-29 |
산텐 세이야꾸 가부시키가이샤 |
결막하 데포에 의한 약물 송달 시스템
|
|
JP2004196787A
(ja)
*
|
2002-12-04 |
2004-07-15 |
Santen Pharmaceut Co Ltd |
結膜下デポによるドラッグデリバリーシステム
|
|
US20040137059A1
(en)
*
|
2003-01-09 |
2004-07-15 |
Thierry Nivaggioli |
Biodegradable ocular implant
|
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
|
US20060115522A1
(en)
*
|
2003-02-17 |
2006-06-01 |
Cipla Ltd |
Pharmaceutical composition
|
|
US8012115B2
(en)
*
|
2003-02-18 |
2011-09-06 |
S.K. Pharmaceuticals, Inc. |
Optic nerve implants
|
|
US20060167435A1
(en)
*
|
2003-02-18 |
2006-07-27 |
Adamis Anthony P |
Transscleral drug delivery device and related methods
|
|
US20060074061A1
(en)
*
|
2003-02-20 |
2006-04-06 |
Bingaman David P |
Formulations of glucocorticoids to treat pathologic ocular angiogenesis
|
|
WO2004073607A2
(en)
*
|
2003-02-20 |
2004-09-02 |
Alcon, Inc. |
Use of steroids to treat ocular disorders
|
|
US7589107B2
(en)
|
2003-05-19 |
2009-09-15 |
Othera Holding, Inc. |
Amelioration of vitrectomy-induced cataracts
|
|
US7825134B2
(en)
*
|
2003-05-19 |
2010-11-02 |
Othera Holding, Inc. |
Amelioration of cataracts, macular degeneration and other ophthalmic diseases
|
|
CA2527121A1
(en)
*
|
2003-06-13 |
2004-12-29 |
Alcon, Inc. |
Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
|
|
US20040253293A1
(en)
*
|
2003-06-16 |
2004-12-16 |
Afshin Shafiee |
Rate controlled release of a pharmaceutical agent in a biodegradable device
|
|
RU2248777C1
(ru)
*
|
2003-06-18 |
2005-03-27 |
Государственное учреждение Межотраслевой научно-технический комлекс "Микрохирургия глаза" им. акад. С.Н. Федорова |
Способ доставки лекарственных веществ к заднему отрезку глазного яблока при интравитреальных вмешательствах по поводу отслойки сетчатки, осложненной пролиферативной витреоретинопатией
|
|
US8790637B2
(en)
*
|
2003-06-27 |
2014-07-29 |
DePuy Synthes Products, LLC |
Repair and regeneration of ocular tissue using postpartum-derived cells
|
|
US20190105351A9
(en)
*
|
2003-06-27 |
2019-04-11 |
Ethicon, Incorporated |
Systemically and locally administered cells for neuropathic pain
|
|
US8491883B2
(en)
*
|
2003-06-27 |
2013-07-23 |
Advanced Technologies And Regenerative Medicine, Llc |
Treatment of amyotrophic lateral sclerosis using umbilical derived cells
|
|
EP1641915B1
(en)
*
|
2003-06-27 |
2016-07-27 |
DePuy Synthes Products, Inc. |
Repair and regeneration of ocular tissue using postpartum-derived cells
|
|
US9572840B2
(en)
|
2003-06-27 |
2017-02-21 |
DePuy Synthes Products, Inc. |
Regeneration and repair of neural tissue using postpartum-derived cells
|
|
US20100158880A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Ethicon, Incorporated |
Regeneration and repair of neural tissue following injury
|
|
US7875272B2
(en)
|
2003-06-27 |
2011-01-25 |
Ethicon, Incorporated |
Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
|
|
US9592258B2
(en)
|
2003-06-27 |
2017-03-14 |
DePuy Synthes Products, Inc. |
Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
|
|
US8518390B2
(en)
|
2003-06-27 |
2013-08-27 |
Advanced Technologies And Regenerative Medicine, Llc |
Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
|
|
CN1835735B
(zh)
*
|
2003-08-20 |
2010-05-12 |
参天制药株式会社 |
微粒眼球筋膜下给药的药物释放系统
|
|
US20050209141A1
(en)
*
|
2003-10-17 |
2005-09-22 |
Silver Randi B |
Mast cell-derived renin
|
|
US20050101582A1
(en)
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
|
RU2336074C2
(ru)
*
|
2003-11-12 |
2008-10-20 |
Аллерган, Инк. |
Композиции и способы лечения заднего сегмента глаза
|
|
US20090148527A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Robinson Michael R |
Intraocular formulation
|
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
|
CN100558360C
(zh)
*
|
2003-11-20 |
2009-11-11 |
奥特拉控股公司 |
羟胺组合物在制备缓解黄斑变性和其他眼科疾病的药物中的用途
|
|
US20080220049A1
(en)
*
|
2003-12-05 |
2008-09-11 |
Adnexus, A Bristol-Myers Squibb R&D Company |
Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
|
|
SG149004A1
(en)
|
2003-12-05 |
2009-01-29 |
Bristol Myers Squibb Co |
Inhibitors of type 2 vascular endothelial growth factor receptors
|
|
WO2005061003A1
(en)
*
|
2003-12-12 |
2005-07-07 |
Medtronic, Inc. |
Anti-infective medical device
|
|
US8691258B2
(en)
*
|
2003-12-12 |
2014-04-08 |
Medtronic, Inc. |
Anti-infective medical device
|
|
AU2005209201B2
(en)
|
2004-01-20 |
2010-06-03 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
|
US7771742B2
(en)
*
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
|
US8591885B2
(en)
*
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
|
US8425929B2
(en)
*
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
|
WO2005110374A1
(en)
|
2004-04-30 |
2005-11-24 |
Allergan, Inc. |
Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
|
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
|
US20050244500A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
|
BRPI0510485A
(pt)
|
2004-04-30 |
2007-11-13 |
Allergan Inc |
implantes inibidores de tirosina cinase intravìtreos biodegradáveis
|
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
|
US20070212395A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Allergan, Inc. |
Ocular therapy using sirtuin-activating agents
|
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
|
US8685435B2
(en)
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
|
US20060182781A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Methods for treating ocular conditions with cyclic lipid contraining microparticles
|
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
|
US20050244463A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
|
US8529927B2
(en)
*
|
2004-04-30 |
2013-09-10 |
Allergan, Inc. |
Alpha-2 agonist polymeric drug delivery systems
|
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
|
US7589057B2
(en)
|
2004-04-30 |
2009-09-15 |
Allergan, Inc. |
Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
|
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
|
US20070059336A1
(en)
*
|
2004-04-30 |
2007-03-15 |
Allergan, Inc. |
Anti-angiogenic sustained release intraocular implants and related methods
|
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
|
US20060182783A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems
|
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
|
US8119154B2
(en)
*
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
|
US8147865B2
(en)
*
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
|
AU2011213904B2
(en)
*
|
2004-04-30 |
2014-06-05 |
Allergan, Inc. |
Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies
|
|
US20070254950A1
(en)
*
|
2004-05-25 |
2007-11-01 |
Othera Pharmaceuticals, Inc. |
Oculoselective Drugs and Prodrugs
|
|
WO2006014484A2
(en)
|
2004-07-02 |
2006-02-09 |
Surmodics, Inc. |
Methods and devices for the treatment of ocular conditions
|
|
AU2013221985B2
(en)
*
|
2004-07-12 |
2016-09-01 |
Allergan, Inc. |
Ophthalmic compositions and methods for treating ophthalmic conditions
|
|
BRPI0513243B8
(pt)
*
|
2004-07-12 |
2021-05-25 |
Allergan Inc |
composições oftálmicas e respectivos usos
|
|
US8541028B2
(en)
|
2004-08-04 |
2013-09-24 |
Evonik Corporation |
Methods for manufacturing delivery devices and devices thereof
|
|
US20060116404A1
(en)
|
2004-09-24 |
2006-06-01 |
Gary Robinson |
CAI-based systems and methods for the localized treatment of ocular and other diseases
|
|
US20160106717A1
(en)
|
2004-09-24 |
2016-04-21 |
Gen Pharma Holdings LLC |
Cai-based systems and methods for the localized treatment of uveitis
|
|
US20060068012A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Bausch & Lomb Incorporated |
Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control
|
|
US20060067978A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Bausch & Lomb Incorporated |
Process for preparing poly(vinyl alcohol) drug delivery devices
|
|
CN101060831B
(zh)
|
2004-10-01 |
2010-06-23 |
拉姆斯科股份有限公司 |
可方便植入的缓释药物组合物
|
|
US20080038316A1
(en)
*
|
2004-10-01 |
2008-02-14 |
Wong Vernon G |
Conveniently implantable sustained release drug compositions
|
|
US8541413B2
(en)
*
|
2004-10-01 |
2013-09-24 |
Ramscor, Inc. |
Sustained release eye drop formulations
|
|
US9993558B2
(en)
|
2004-10-01 |
2018-06-12 |
Ramscor, Inc. |
Sustained release eye drop formulations
|
|
WO2006043965A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
|
US20060275230A1
(en)
|
2004-12-10 |
2006-12-07 |
Frank Kochinke |
Compositions and methods for treating conditions of the nail unit
|
|
TW200637618A
(en)
|
2004-12-10 |
2006-11-01 |
Talima Therapeutics Inc |
Compositions and methods for treating conditions of the nail unit
|
|
WO2006101548A2
(en)
*
|
2004-12-21 |
2006-09-28 |
Ethicon, Inc. |
Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
|
|
US20060153815A1
(en)
*
|
2004-12-21 |
2006-07-13 |
Agnieszka Seyda |
Tissue engineering devices for the repair and regeneration of tissue
|
|
WO2006083394A2
(en)
*
|
2004-12-21 |
2006-08-10 |
Ethicon, Inc. |
Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
|
|
US20060134174A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Bausch & Lomb Incorporated |
Pharmaceutical delivery system and method of use
|
|
US20060134175A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Stephen Bartels |
Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
|
|
EP1833496B1
(en)
|
2004-12-23 |
2013-07-31 |
Ethicon, Incorporated |
Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
|
|
ES2621847T3
(es)
|
2004-12-23 |
2017-07-05 |
DePuy Synthes Products, Inc. |
Células posparto derivadas de tejido de cordón umbilical, y métodos de elaboración y uso de las mismas
|
|
WO2006071769A1
(en)
*
|
2004-12-28 |
2006-07-06 |
The Trustees Of The University Of Pennsylvania |
Controlled release from block co-polymer worm micelles
|
|
US20060204548A1
(en)
|
2005-03-01 |
2006-09-14 |
Allergan, Inc. |
Microimplants for ocular administration
|
|
US20060233858A1
(en)
*
|
2005-03-08 |
2006-10-19 |
Allergan, Inc. |
Systems and methods providing targeted intraocular drug delivery
|
|
US8003124B2
(en)
*
|
2005-04-08 |
2011-08-23 |
Surmodics, Inc. |
Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
|
|
US7931909B2
(en)
|
2005-05-10 |
2011-04-26 |
Allergan, Inc. |
Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
|
|
US20080312283A1
(en)
*
|
2005-05-26 |
2008-12-18 |
Othera Pharmaceuticals, Inc. |
Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts
|
|
WO2007014327A2
(en)
|
2005-07-27 |
2007-02-01 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
|
WO2007037849A2
(en)
*
|
2005-09-16 |
2007-04-05 |
Allergan, Inc. |
Compositions and methods for the intraocular transport of therapeutic agents
|
|
CA2623638A1
(en)
|
2005-09-30 |
2007-04-12 |
Vitae Pharmaceuticals, Inc. |
Treatment of cancer with specific rxr agonists
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
WO2007047626A1
(en)
*
|
2005-10-14 |
2007-04-26 |
Alcon, Inc. |
Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
|
|
CA2602577C
(en)
|
2005-10-18 |
2015-03-31 |
Allergan, Inc. |
Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
|
|
UA94427C2
(ru)
|
2005-11-29 |
2011-05-10 |
Смиткляйн Бичам Корпорейшн |
Фармацевтическая композиция для местного лечения неоваскулярных расстройств глаз
|
|
JP5289970B2
(ja)
*
|
2005-12-16 |
2013-09-11 |
エシコン・インコーポレイテッド |
組織適合性不適合な移植における逆免疫反応を抑制するための組成物および方法
|
|
WO2007073552A1
(en)
*
|
2005-12-19 |
2007-06-28 |
Ethicon, Inc. |
In vitro expansion of postpartum derived cells in roller bottles
|
|
US9125906B2
(en)
|
2005-12-28 |
2015-09-08 |
DePuy Synthes Products, Inc. |
Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
|
|
EP1979050B1
(en)
*
|
2005-12-28 |
2017-04-19 |
DePuy Synthes Products, Inc. |
Treatment of peripheral vascular disease using postpartum-derived cells
|
|
US7756524B1
(en)
|
2006-01-31 |
2010-07-13 |
Nextel Communications Inc. |
System and method for partially count-based allocation of vocoder resources
|
|
US20070178138A1
(en)
*
|
2006-02-01 |
2007-08-02 |
Allergan, Inc. |
Biodegradable non-opthalmic implants and related methods
|
|
EP2397148A3
(en)
|
2006-02-02 |
2012-04-25 |
Allergan, Inc. |
Compositions and methods for the treatment of ophthalmic disease
|
|
US20070203190A1
(en)
*
|
2006-02-22 |
2007-08-30 |
Ghanshyam Patil |
Hydroxylamines and derivatives for the inhibition of complement activation
|
|
SG170806A1
(en)
|
2006-03-31 |
2011-05-30 |
Qlt Plug Delivery Inc |
Nasolacrimal drainage system implants for drug therapy
|
|
US20070232660A1
(en)
*
|
2006-04-04 |
2007-10-04 |
Allergan, Inc. |
Therapeutic and delivery methods of prostaglandin ep4 agonists
|
|
US20070260203A1
(en)
*
|
2006-05-04 |
2007-11-08 |
Allergan, Inc. |
Vasoactive agent intraocular implant
|
|
US8668676B2
(en)
*
|
2006-06-19 |
2014-03-11 |
Allergan, Inc. |
Apparatus and methods for implanting particulate ocular implants
|
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
|
US20070298073A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
|
US9039761B2
(en)
|
2006-08-04 |
2015-05-26 |
Allergan, Inc. |
Ocular implant delivery assemblies with distal caps
|
|
CA2664879C
(en)
*
|
2006-09-29 |
2015-03-24 |
Surmodics, Inc. |
Biodegradable ocular implants and methods for treating ocular conditions
|
|
DE602007008125D1
(de)
|
2006-10-31 |
2010-09-09 |
Surmodics Pharmaceuticals Inc |
Kugelförmige polymer-teilchen
|
|
US8586556B2
(en)
*
|
2006-11-03 |
2013-11-19 |
Allergan, Inc. |
Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
|
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
|
JP5537946B2
(ja)
|
2006-11-22 |
2014-07-02 |
ブリストル−マイヤーズ スクイブ カンパニー |
Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
|
|
US8969415B2
(en)
*
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
|
CA2670990A1
(en)
|
2006-12-01 |
2008-06-12 |
Allergan, Inc. |
Method for determining optimum intraocular locations for drug delivery systems
|
|
US8846073B2
(en)
*
|
2006-12-19 |
2014-09-30 |
Allergan, Inc. |
Low temperature processes for making cyclic lipid implants for intraocular use
|
|
US20090092574A1
(en)
|
2006-12-29 |
2009-04-09 |
Scott Richard W |
Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
|
|
US20080280890A1
(en)
|
2007-02-22 |
2008-11-13 |
Ghanshyam Patil |
Hydroxylamine compounds and methods of their use
|
|
US7911053B2
(en)
*
|
2007-04-19 |
2011-03-22 |
Marvell World Trade Ltd. |
Semiconductor packaging with internal wiring bus
|
|
IN266731B
(enExample)
*
|
2007-05-14 |
2015-05-28 |
Sustained Nano Systems Llc |
|
|
US8231892B2
(en)
*
|
2007-05-24 |
2012-07-31 |
Allergan, Inc. |
Biodegradable drug delivery system
|
|
US20080317805A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Mckay William F |
Locally administrated low doses of corticosteroids
|
|
WO2009029543A1
(en)
*
|
2007-08-24 |
2009-03-05 |
Aegis Therapeutics, Llc |
Controlled release formulations
|
|
US20090123508A1
(en)
*
|
2007-10-04 |
2009-05-14 |
Boston Scientific Scimed, Inc. |
Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
|
|
JP5323845B2
(ja)
*
|
2007-10-05 |
2013-10-23 |
エシコン・インコーポレイテッド |
ヒト臍帯組織由来細胞を用いた腎組織の修復および再建
|
|
ES2667945T3
(es)
|
2007-10-08 |
2018-05-16 |
Aurinia Pharmaceuticals Inc. |
Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
|
|
US8124601B2
(en)
*
|
2007-11-21 |
2012-02-28 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
US8236538B2
(en)
|
2007-12-20 |
2012-08-07 |
Advanced Technologies And Regenerative Medicine, Llc |
Methods for sterilizing materials containing biologically active agents
|
|
ES2718612T3
(es)
|
2007-12-20 |
2019-07-03 |
Evonik Corp |
Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
|
|
AU2009213141A1
(en)
|
2008-02-14 |
2009-08-20 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins that bind EGFR
|
|
US9192571B2
(en)
|
2008-03-03 |
2015-11-24 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating or preventing ocular pain
|
|
RU2431469C1
(ru)
*
|
2008-03-03 |
2011-10-20 |
Аллерган, Инк. |
Композиции кеторолака трометамина для лечения или профилактики глазной боли
|
|
US8524267B2
(en)
|
2008-04-18 |
2013-09-03 |
Warsaw Orthopedic, Inc. |
Dexamethasone formulations in a biodegradable material
|
|
US10064819B2
(en)
|
2008-05-12 |
2018-09-04 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
|
US9095404B2
(en)
|
2008-05-12 |
2015-08-04 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
|
AU2009246520B2
(en)
|
2008-05-12 |
2012-04-19 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
|
US9877973B2
(en)
|
2008-05-12 |
2018-01-30 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
|
US10588855B2
(en)
|
2008-05-12 |
2020-03-17 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
|
PE20091931A1
(es)
|
2008-05-22 |
2009-12-31 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
|
US10517839B2
(en)
*
|
2008-06-09 |
2019-12-31 |
Cornell University |
Mast cell inhibition in diseases of the retina and vitreous
|
|
US8821870B2
(en)
|
2008-07-18 |
2014-09-02 |
Allergan, Inc. |
Method for treating atrophic age related macular degeneration
|
|
EP2320911B1
(en)
|
2008-08-01 |
2014-10-08 |
Eye Therapies LLC |
Vasoconstriction compositions and methods of use
|
|
US12246013B2
(en)
|
2008-08-01 |
2025-03-11 |
Eye Therapies Llc |
Vasoconstriction compositions and methods of use
|
|
JP5529874B2
(ja)
*
|
2008-09-25 |
2014-06-25 |
インヴィーヴォ セラプーティクス コーポレーション |
脊髄の損傷、炎症および免疫疾患に用いられる局所的に放出を制御しうる治療薬
|
|
US20100104654A1
(en)
|
2008-10-27 |
2010-04-29 |
Allergan, Inc. |
Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
|
|
US9095506B2
(en)
|
2008-11-17 |
2015-08-04 |
Allergan, Inc. |
Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
|
|
US8034813B2
(en)
|
2008-11-18 |
2011-10-11 |
Bausch & Lomb Incorporated |
Polymorphs of brimonidine pamoate
|
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
|
|
US10557116B2
(en)
|
2008-12-19 |
2020-02-11 |
DePuy Synthes Products, Inc. |
Treatment of lung and pulmonary diseases and disorders
|
|
US10179900B2
(en)
*
|
2008-12-19 |
2019-01-15 |
DePuy Synthes Products, Inc. |
Conditioned media and methods of making a conditioned media
|
|
US8545554B2
(en)
*
|
2009-01-16 |
2013-10-01 |
Allergan, Inc. |
Intraocular injector
|
|
US20100291182A1
(en)
*
|
2009-01-21 |
2010-11-18 |
Arsenal Medical, Inc. |
Drug-Loaded Fibers
|
|
US20100204325A1
(en)
|
2009-02-11 |
2010-08-12 |
Allergan, Inc. |
Valproic acid drug delivery systems and intraocular therapeutic uses thereof
|
|
US9636255B2
(en)
|
2009-02-13 |
2017-05-02 |
Dose Medical Corporation |
Uveoscleral drug delivery implant and methods for implanting the same
|
|
US20100239632A1
(en)
*
|
2009-03-23 |
2010-09-23 |
Warsaw Orthopedic, Inc. |
Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
|
|
SG174551A1
(en)
*
|
2009-03-26 |
2011-10-28 |
Ethicon Inc |
Human umbilical cord tissue cells as therapy for alzheimer' s disease
|
|
US10206813B2
(en)
|
2009-05-18 |
2019-02-19 |
Dose Medical Corporation |
Implants with controlled drug delivery features and methods of using same
|
|
EP3412260B1
(en)
|
2009-05-18 |
2020-08-26 |
Dose Medical Corporation |
Drug eluting ocular implant
|
|
US12478503B2
(en)
|
2009-05-18 |
2025-11-25 |
Glaukos Corporation |
Implants with controlled drug delivery features and methods of using same
|
|
WO2010144194A1
(en)
*
|
2009-06-09 |
2010-12-16 |
Lux Biosciences, Inc. |
Topical drug delivery systems for ophthalmic use
|
|
IN2012DN00352A
(enExample)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
|
GB201111485D0
(en)
|
2011-07-05 |
2011-08-17 |
Biocopea Ltd |
Drug composition and its use in therapy
|
|
US8987241B2
(en)
|
2009-06-19 |
2015-03-24 |
Altos Vision Limited |
Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
|
|
BR112012002709A2
(pt)
*
|
2009-08-05 |
2019-04-30 |
Pieris Ag |
formulações de liberação controlada de muteínas de lipocalina
|
|
US9173817B2
(en)
|
2009-08-24 |
2015-11-03 |
Arsenal Medical, Inc. |
In situ forming hemostatic foam implants
|
|
US10420862B2
(en)
|
2009-08-24 |
2019-09-24 |
Aresenal AAA, LLC. |
In-situ forming foams for treatment of aneurysms
|
|
US20110202016A1
(en)
*
|
2009-08-24 |
2011-08-18 |
Arsenal Medical, Inc. |
Systems and methods relating to polymer foams
|
|
US9044580B2
(en)
|
2009-08-24 |
2015-06-02 |
Arsenal Medical, Inc. |
In-situ forming foams with outer layer
|
|
WO2011039648A1
(en)
|
2009-09-30 |
2011-04-07 |
Glaxo Wellcome Manufacturing Pte Ltd. |
Methods of administration and treatment
|
|
US20120219543A1
(en)
|
2009-10-20 |
2012-08-30 |
Raphael Scharfmann |
Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
|
|
AU2010314990B2
(en)
|
2009-11-09 |
2015-10-01 |
Allergan, Inc. |
Compositions and methods for stimulating hair growth
|
|
US20120245505A1
(en)
|
2009-12-16 |
2012-09-27 |
Robinson Michael R |
Intracameral devices for sustained delivery
|
|
CN107184544A
(zh)
|
2010-01-22 |
2017-09-22 |
阿勒根公司 |
前房内持续释放治疗药植入物
|
|
WO2011106697A1
(en)
|
2010-02-25 |
2011-09-01 |
Schepens Eye Research Institute |
Therapeutic compositions for the treatment of dry eye disease
|
|
JP6182313B2
(ja)
|
2010-03-08 |
2017-08-16 |
スペクトラム ファーマシューティカルズ インコーポレイテッド |
癌治療のためのチオキサントンをベースとしたオートファジー阻害剤療法
|
|
EP2566501B1
(en)
|
2010-05-04 |
2019-03-13 |
Corium International, Inc. |
Method and device for transdermal delivery of parathyroid hormone using a microprojection array
|
|
ES2641144T3
(es)
|
2010-05-10 |
2017-11-07 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
|
|
ES2573108T3
(es)
|
2010-05-26 |
2016-06-06 |
Bristol-Myers Squibb Company |
Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
|
|
WO2011159824A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
Composition and method for treating overactive bladder
|
|
WO2011163560A1
(en)
|
2010-06-25 |
2011-12-29 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Methods of treatment using sterculic acid
|
|
EP2595602B1
(en)
|
2010-07-21 |
2018-05-23 |
Allergan, Inc. |
SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY
|
|
US8697057B2
(en)
|
2010-08-19 |
2014-04-15 |
Allergan, Inc. |
Compositions and soft tissue replacement methods
|
|
EP2605762A1
(en)
|
2010-08-19 |
2013-06-26 |
Allergan, Inc. |
Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
|
|
EP2654715B1
(en)
|
2010-11-24 |
2017-01-25 |
Dose Medical Corporation |
Drug eluting ocular implant
|
|
US20140024627A1
(en)
|
2011-01-03 |
2014-01-23 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
|
|
US8349005B2
(en)
|
2011-01-03 |
2013-01-08 |
Masatoshi Murata |
Method for burying implant to choroid
|
|
US9034240B2
(en)
|
2011-01-31 |
2015-05-19 |
Arsenal Medical, Inc. |
Electrospinning process for fiber manufacture
|
|
US9194058B2
(en)
|
2011-01-31 |
2015-11-24 |
Arsenal Medical, Inc. |
Electrospinning process for manufacture of multi-layered structures
|
|
US8968626B2
(en)
|
2011-01-31 |
2015-03-03 |
Arsenal Medical, Inc. |
Electrospinning process for manufacture of multi-layered structures
|
|
EP2675491A2
(en)
|
2011-02-17 |
2013-12-25 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
|
WO2013105997A2
(en)
|
2011-02-23 |
2013-07-18 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
|
RU2013157087A
(ru)
|
2011-06-03 |
2015-07-20 |
Аллерган, Инк. |
Целевая доставка ретиноидных соединений к сальным железам
|
|
US10245178B1
(en)
|
2011-06-07 |
2019-04-02 |
Glaukos Corporation |
Anterior chamber drug-eluting ocular implant
|
|
WO2012174064A1
(en)
|
2011-06-14 |
2012-12-20 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
|
CN103889434B
(zh)
|
2011-06-21 |
2017-02-15 |
Bvw控股公司 |
含有乳香酸的医疗装置
|
|
ES2666857T3
(es)
|
2011-07-18 |
2018-05-08 |
Mor-Research Applications Ltd. |
Un dispositivo para ajustar la presión intraocular
|
|
AU2012325341B2
(en)
|
2011-10-19 |
2017-01-05 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
|
US8993831B2
(en)
|
2011-11-01 |
2015-03-31 |
Arsenal Medical, Inc. |
Foam and delivery system for treatment of postpartum hemorrhage
|
|
AU2012346214B2
(en)
|
2011-11-30 |
2017-09-14 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
|
JP6322142B2
(ja)
|
2011-12-01 |
2018-05-09 |
ビカム ファーマスーティカルス，インコーポレイテッド |
オプシン結合性リガンド、組成物、及び使用方法
|
|
AU2012347926B2
(en)
|
2011-12-05 |
2018-03-15 |
Incept, Llc |
Medical organogel processes and compositions
|
|
AU2012352149B2
(en)
|
2011-12-13 |
2017-06-01 |
Io Therapeutics, Inc. |
Autoimmune disorder treatment using RXR agonists
|
|
US10653650B2
(en)
|
2011-12-13 |
2020-05-19 |
Io Therapeutics, Inc. |
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
|
|
BR112014015424A2
(pt)
|
2011-12-23 |
2018-05-22 |
Depuy Synthes Products Llc |
detecção de células derivadas de tecido do cordão umbilical humano
|
|
US20130183435A1
(en)
*
|
2012-01-13 |
2013-07-18 |
Hongmin Sun |
Low temperature plasma coating for anti-biofilm formation
|
|
WO2013123274A1
(en)
|
2012-02-16 |
2013-08-22 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
|
WO2013123275A1
(en)
|
2012-02-16 |
2013-08-22 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
|
EP2814482A1
(en)
|
2012-02-16 |
2014-12-24 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
|
WO2013123272A1
(en)
|
2012-02-16 |
2013-08-22 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
|
ES2734554T3
(es)
|
2012-09-26 |
2019-12-10 |
Tangent Reprofiling Ltd |
Combinación de benzo(iso)oxazolpiperidinas con ácido linoleico conjugado
|
|
KR20150058510A
(ko)
*
|
2012-09-27 |
2015-05-28 |
알레간 인코포레이티드 |
단백질의 지속된 방출을 위한 생물분해성 약물 전달 시스템
|
|
WO2014058742A1
(en)
|
2012-10-09 |
2014-04-17 |
Sears Douglas |
Therapeutic treatment
|
|
CA2889035A1
(en)
|
2012-10-24 |
2014-05-01 |
Biocopea Limited |
Drug combinations and uses
|
|
PL3660033T3
(pl)
|
2012-11-15 |
2021-12-06 |
Apellis Pharmaceuticals, Inc. |
Analogi kompstatyny oraz powiązane kompozycje i sposoby
|
|
MX375307B
(es)
|
2012-12-21 |
2025-03-06 |
Corium Inc |
Microarreglo para la entrega de agente terapeutico y metodos de uso.
|
|
JP6513576B2
(ja)
|
2013-01-14 |
2019-05-15 |
ヘルス クリニックス リミテッド |
抗がん剤および使用
|
|
NZ710444A
(en)
|
2013-02-11 |
2020-08-28 |
Univ California |
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
|
|
US20140234389A1
(en)
|
2013-02-15 |
2014-08-21 |
Allergan, Inc. |
Sustained drug delivery implant
|
|
MY170528A
(en)
|
2013-02-18 |
2019-08-09 |
Vegenics Pty Ltd |
Vegfr-3 ligand binding molecules and uses thereof
|
|
WO2014164703A1
(en)
|
2013-03-11 |
2014-10-09 |
University Of Florida Research Foundation, Inc. |
Delivery of card protein as therapy for occular inflammation
|
|
EP2970145B1
(en)
|
2013-03-11 |
2020-05-06 |
The Broad Institute, Inc. |
Compounds and compositions for the treatment of cancer
|
|
EP2968887B1
(en)
|
2013-03-12 |
2022-05-04 |
Corium, Inc. |
Microprojection applicators
|
|
WO2014165023A1
(en)
|
2013-03-12 |
2014-10-09 |
Carnegie Mellon University |
Coated vaso-occclusive device for treatment of aneurysms
|
|
CN105377355A
(zh)
|
2013-03-14 |
2016-03-02 |
拇趾公司 |
治疗甲单元的感染、疾病或病症的方法
|
|
US10308687B2
(en)
|
2013-03-15 |
2019-06-04 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
MX380204B
(es)
|
2013-03-15 |
2025-03-12 |
Corium Inc |
Micrordenamiento para suministro de agente terapeútico y métodos de uso.
|
|
WO2014151769A1
(en)
|
2013-03-15 |
2014-09-25 |
Allergan, Inc. |
Compositions including encapsulated isotretinoin and methods for use thereof
|
|
US10517759B2
(en)
|
2013-03-15 |
2019-12-31 |
Glaukos Corporation |
Glaucoma stent and methods thereof for glaucoma treatment
|
|
EP2994758B1
(en)
|
2013-05-08 |
2017-12-20 |
Opthea Limited |
Biomarkers for age-related macular degeneration (amd)
|
|
KR102373982B1
(ko)
|
2013-08-21 |
2022-03-14 |
센세오닉스, 인코포레이티드 |
생-감지 분석물의 생체 내 보호를 위한 약물 용출
|
|
JP6543431B2
(ja)
*
|
2013-10-10 |
2019-07-10 |
ユニバーシティー オブ ユタ リサーチ ファウンデーションＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｕｔａｈ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ |
眼内薬物送達デバイスおよび付随する方法
|
|
EP3099290A1
(en)
|
2014-01-28 |
2016-12-07 |
Allergan, Inc. |
Topical retinoid formulations and methods of use
|
|
AU2015217152A1
(en)
|
2014-02-11 |
2016-08-11 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
JP6510497B2
(ja)
|
2014-04-17 |
2019-05-08 |
株式会社シード |
アニオン性薬物含有医療用デバイス
|
|
US20150342875A1
(en)
|
2014-05-29 |
2015-12-03 |
Dose Medical Corporation |
Implants with controlled drug delivery features and methods of using same
|
|
US20160008376A1
(en)
|
2014-07-10 |
2016-01-14 |
Biocopea Limited |
Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders
|
|
US10624843B2
(en)
|
2014-09-04 |
2020-04-21 |
Corium, Inc. |
Microstructure array, methods of making, and methods of use
|
|
BR112017019025A2
(pt)
|
2015-03-06 |
2018-07-31 |
Envisia Therapeutics Inc |
aplicadores de implante e métodos para administrar implantes.
|
|
WO2017004067A1
(en)
|
2015-06-29 |
2017-01-05 |
Corium International, Inc. |
Microarray for delivery of therapeutic agent, methods of use, and methods of making
|
|
CN115337254A
(zh)
|
2015-07-23 |
2022-11-15 |
爱瑞制药公司 |
用于治疗眼病的玻璃体内药物递送系统
|
|
HUE051165T2
(hu)
|
2015-07-29 |
2021-03-01 |
Allergan Inc |
ANG-2 elleni, csak nehézláncot tartalmazó antitestek
|
|
WO2017030909A1
(en)
|
2015-08-14 |
2017-02-23 |
Allergan, Inc. |
Heavy chain only antibodies to pdgf
|
|
EP3344248B1
(en)
|
2015-09-02 |
2022-03-23 |
Trevena, Inc. |
6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
|
|
US11925578B2
(en)
|
2015-09-02 |
2024-03-12 |
Glaukos Corporation |
Drug delivery implants with bi-directional delivery capacity
|
|
WO2017053885A1
(en)
|
2015-09-25 |
2017-03-30 |
Glaukos Corporation |
Punctal implants with controlled drug delivery features and methods of using same
|
|
CN108431019A
(zh)
|
2015-10-07 |
2018-08-21 |
阿佩利斯制药有限公司 |
给药方案
|
|
EP4088719A1
(en)
|
2015-10-13 |
2022-11-16 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
|
US12048761B2
(en)
*
|
2015-10-13 |
2024-07-30 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
|
JP6835836B2
(ja)
|
2015-10-13 |
2021-02-24 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
脈絡膜血管新生の処置のための方法及び医薬組成物
|
|
KR102489706B1
(ko)
|
2015-10-31 |
2023-01-17 |
아이오 테라퓨틱스, 인크. |
Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
|
|
PT109154B
(pt)
*
|
2016-02-12 |
2019-11-05 |
Univ De Coimbra |
Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
|
|
EP3426303B1
(en)
|
2016-03-10 |
2022-06-15 |
IO Therapeutics, Inc. |
Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
|
|
MX386643B
(es)
|
2016-03-10 |
2025-03-19 |
Io Therapeutics Inc |
Tratamiento contra enfermedades autoinmunitarias con combinaciones de agonistas rxr y hormonas tiroideas.
|
|
WO2017173327A1
(en)
|
2016-03-31 |
2017-10-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
|
US20190125669A1
(en)
*
|
2016-04-17 |
2019-05-02 |
Children's Medical Center Corporation |
Systems and methods for steroidal gels
|
|
JP7003110B2
(ja)
|
2016-04-20 |
2022-01-20 |
ドーズ メディカル コーポレーション |
生体吸収性眼球薬物送達デバイス
|
|
US20180015129A1
(en)
|
2016-07-05 |
2018-01-18 |
Janssen Biotech, Inc. |
Treatment of retinal vascular disease using progenitor cells
|
|
AU2017312499B2
(en)
|
2016-08-19 |
2023-02-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
|
|
JP2019534063A
(ja)
|
2016-09-02 |
2019-11-28 |
エンビシャ セラピューティクス インコーポレイテッド |
インプラントアプリケータ
|
|
EP4520828A3
(en)
|
2016-11-15 |
2025-07-09 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
|
CN110446495B
(zh)
|
2017-02-17 |
2023-09-05 |
特维娜有限公司 |
含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
|
|
CA3052480A1
(en)
|
2017-02-17 |
2018-08-23 |
Trevena, Inc. |
5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
|
|
CN110831544B
(zh)
|
2017-04-07 |
2022-11-18 |
阿佩利斯制药有限公司 |
长效坎普他汀类似物、其组合物的给药方案及其医药用途
|
|
JP7171060B2
(ja)
|
2017-05-05 |
2022-11-15 |
ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
マトリックス結合ベシクル（ｍｂｖ）の眼適用
|
|
US20190224275A1
(en)
|
2017-05-12 |
2019-07-25 |
Aurinia Pharmaceuticals Inc. |
Protocol for treatment of lupus nephritis
|
|
CA3067695A1
(en)
|
2017-06-21 |
2018-12-27 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
EP4234025A3
(en)
|
2017-08-11 |
2024-04-24 |
Unity Biotechnology, Inc. |
Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
|
|
US11517549B2
(en)
|
2017-09-20 |
2022-12-06 |
Io Therapeutics, Inc. |
Treatment of disease with esters of selective RXR agonists
|
|
US11260048B2
(en)
|
2017-10-03 |
2022-03-01 |
The Schepens Eye Research Institute, Inc. |
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
|
WO2022082213A1
(en)
|
2017-10-16 |
2022-04-21 |
Retriever Medical, Inc. |
Clot removal methods and devices with multiple independently controllable elements
|
|
US12201315B2
(en)
|
2017-10-16 |
2025-01-21 |
Retriever Medical, Inc. |
Clot removal methods and devices with multiple independently controllable elements
|
|
US10172634B1
(en)
|
2017-10-16 |
2019-01-08 |
Michael Bruce Horowitz |
Catheter based retrieval device with proximal body having axial freedom of movement
|
|
EP3710008A4
(en)
|
2017-11-14 |
2021-08-25 |
The Schepens Eye Research Institute, Inc. |
RUNX1 INHIBITION FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND DISEASES ASSOCIATED WITH EPITHELIAL-MESENCHYMAL TRANSITION
|
|
WO2019118938A1
(en)
|
2017-12-15 |
2019-06-20 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens and related compositions and methods
|
|
CA3091810A1
(en)
|
2018-03-02 |
2019-09-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of il-34 to treat retinal inflammation and neurodegeneration
|
|
SG11202010742UA
(en)
|
2018-05-01 |
2020-11-27 |
Chibi Inc |
Liquid depot for non-invasive sustained delivery of agents to the eye
|
|
CA3097926A1
(en)
*
|
2018-05-01 |
2019-11-07 |
Chibi, Inc. |
Eye drop formulation and method for sustained delivery of medicament to the retina
|
|
WO2020092897A1
(en)
|
2018-11-02 |
2020-05-07 |
Senseonics, Incorporated |
Drug eluting matrix on analyte indicator
|
|
US10966950B2
(en)
|
2019-06-11 |
2021-04-06 |
Io Therapeutics, Inc. |
Use of an RXR agonist in treating HER2+ cancers
|
|
US11471426B2
(en)
|
2019-10-16 |
2022-10-18 |
American River Nutrition, Llc |
Compositions comprising quinone and/or quinol and methods of preparations and use thereof
|
|
KR20220084381A
(ko)
*
|
2019-12-10 |
2022-06-21 |
알콘 인코포레이티드 |
생분해성 중합체를 갖는 용해성 중합체 눈 삽입물
|
|
CA3165922A1
(en)
|
2020-01-17 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Gene therapy for treatment of crx-autosomal dominant retinopathies
|
|
US20240374599A1
(en)
|
2020-02-26 |
2024-11-14 |
Case Western Reserve University |
Compositions and methods for treating misfolded protein ocular disorders
|
|
WO2021244964A1
(en)
|
2020-06-01 |
2021-12-09 |
Black Cat Bio Limited |
Compositions and methods for treating infections and netopathy
|
|
GB202018889D0
(en)
*
|
2020-12-01 |
2021-01-13 |
UCB Biopharma SRL |
Formulations
|
|
WO2023105417A1
(en)
|
2021-12-06 |
2023-06-15 |
Breye Therapeutics Aps |
Danegaptide formulation for applicatoin in the eye
|
|
KR20240115316A
(ko)
|
2021-12-07 |
2024-07-25 |
아이오 테라퓨틱스, 인크. |
약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도
|
|
KR20240119103A
(ko)
|
2021-12-07 |
2024-08-06 |
아이오 테라퓨틱스, 인크. |
Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도
|
|
US11779553B1
(en)
*
|
2022-11-28 |
2023-10-10 |
Atif B. D. Collins |
Methods and devices for treatment of eyelid ptosis
|
|
AU2024240009A1
(en)
|
2023-03-17 |
2025-09-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for treatment of age-related macular degeneration
|